A detailed history of Corient Capital Partners, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Corient Capital Partners, LLC holds 1,896 shares of REGN stock, worth $1.32 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
1,896
Previous 1,896 -0.0%
Holding current value
$1.32 Million
Previous $1.12 Million -0.0%
% of portfolio
0.08%
Previous 0.08%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$548.35 - $738.84 $16,998 - $22,904
31 Added 1.66%
1,896 $1.12 Million
Q1 2022

May 16, 2022

BUY
$595.12 - $698.43 $285,062 - $334,547
479 Added 34.56%
1,865 $1.3 Million
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $22,282 - $27,509
41 Added 3.05%
1,386 $875,000
Q3 2021

Nov 16, 2021

SELL
$574.03 - $680.96 $121,694 - $144,363
-212 Reduced 13.62%
1,345 $814,000
Q2 2021

Aug 16, 2021

BUY
$472.8 - $558.54 $85,104 - $100,537
180 Added 13.07%
1,557 $870,000
Q1 2021

May 17, 2021

BUY
$446.73 - $548.2 $15,635 - $19,187
35 Added 2.61%
1,377 $652,000
Q4 2020

Feb 12, 2021

SELL
$478.3 - $607.98 $195,624 - $248,663
-409 Reduced 23.36%
1,342 $649,000
Q3 2020

Nov 16, 2020

SELL
$544.75 - $658.21 $57,198 - $69,112
-105 Reduced 5.66%
1,751 $980,000
Q2 2020

Aug 14, 2020

BUY
$493.32 - $643.92 $359,630 - $469,417
729 Added 64.69%
1,856 $1.16 Million
Q1 2020

May 06, 2020

BUY
$336.18 - $494.43 $72,951 - $107,291
217 Added 23.85%
1,127 $550,000
Q4 2019

Feb 04, 2020

BUY
$274.13 - $376.51 $249,458 - $342,624
910 New
910 $342,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $74.7B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Corient Capital Partners, LLC Portfolio

Follow Corient Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corient Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Corient Capital Partners, LLC with notifications on news.